摘要
Abstract
Objective To discuss clinical efficacy of interferon-α and entecavir in treatment of HBeAg-positive chronic hepatitis B. Methods Clinical data of 97 cases with HBeAg-positive chronic hepatitis B were retrospectively analyzed. Forty-eight cases of group of interferon-αwere treated by interferon-α, and 49 cases of group of entecavir were treated by entecavir. After 48 weeks, rates of HBeAg loss, HBV DNA<1000 copies/mL, normalization of ALT of two groups were compared.Results After treatment for 48 weeks, HBV DNA<1000 copies/mL, HBeAg loss and normalization of ALT rates of two groups showed no significant differences(P>0.05). HBeAg seroconversion rate of interferon-α group was higher than entecavir group(P<0.01). In interferon-α group, HBeAg level of patients with HBeAg seroconversion was lower than no HBeAg seroconversion patients(P<0.01). ConclusionInterferon-α and entecavir in treatment of chronic hepatitis B show different advantages and disadvantages. In clinical practice, doctors should choose the best treatment options based on the specific circumstances of the patients.关键词
干扰素α/恩替卡韦/血清学转换Key words
Interferon-α/Entecavir/Seroconversion分类
医药卫生
